ATE405576T1 - Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände - Google Patents

Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände

Info

Publication number: ATE405576T1
Authority: AT; Austria
Prior art keywords: compounds; inflammatory; treatment; androstan; alpha
Prior art date: 2005-01-10

Application number

AT06700486T

Other languages

English (en)

Inventor

Keith Biggadike

Deborah Needham

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-09

Publication date

2008-09-15

2005-01-10 Priority claimed from GB0500406A external-priority patent/GB0500406D0/en

2005-09-14 Priority claimed from GB0518775A external-priority patent/GB0518775D0/en

2006-01-09 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE405576T1 publication Critical patent/ATE405576T1/de

Links

230000002757 inflammatory effect Effects 0.000 title abstract 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 title 1
206010020751 Hypersensitivity Diseases 0.000 title 1
208000026935 allergic disease Diseases 0.000 title 1
230000007815 allergy Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
238000004519 manufacturing process Methods 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010027654 Allergic conditions Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Otolaryngology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

AT06700486T 2005-01-10 2006-01-09 Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände ATE405576T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0500406A GB0500406D0 (en)	2005-01-10	2005-01-10	Novel compounds
GB0518775A GB0518775D0 (en)	2005-09-14	2005-09-14	Novel compounds

Publications (1)

Publication Number	Publication Date
ATE405576T1 true ATE405576T1 (de)	2008-09-15

Family

ID=36051466

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06700486T ATE405576T1 (de)	2005-01-10	2006-01-09	Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände

Country Status (7)

Country	Link
US (1)	US20090124588A1 (de)
EP (1)	EP1836215B1 (de)
JP (1)	JP2008526807A (de)
AT (1)	ATE405576T1 (de)
DE (1)	DE602006002366D1 (de)
ES (1)	ES2312104T3 (de)
WO (1)	WO2006072600A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1841780B1 (de) *	2005-01-10	2011-07-27	Glaxo Group Limited	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0523251D0 (en) *	2005-11-15	2005-12-21	Glaxo Group Ltd	Novel compounds
KR20090003349A (ko)	2006-04-20	2009-01-09	글락소 그룹 리미티드	화합물
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
BRPI0912267A2 (pt)	2008-05-23	2015-10-13	Amira Pharmaceuticals Inc	sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
ES2566339T3 (es)	2008-06-05	2016-04-12	Glaxo Group Limited	Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
US8524751B2 (en)	2009-03-09	2013-09-03	GlaxoSmithKline Intellecutual Property Development	4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
JP2012520257A (ja)	2009-03-10	2012-09-06	グラクソグループリミテッド	Ｉｋｋ２阻害剤としてのインドール誘導体
EP2408769A1 (de)	2009-03-17	2012-01-25	Glaxo Group Limited	Als itk-inhibitoren verwendete pyrimidinderivate
EA201171144A1 (ru)	2009-03-19	2012-04-30	Мерк Шарп Энд Домэ Корп.	ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2010107958A1 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408916A2 (de)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	Rna-interferenz-vermittelte hemmung der genexpression von ctgf (connective tissue growth factor) unter verwendung von sina (short interfering nucleic acid)
JP2012520685A (ja)	2009-03-19	2012-09-10	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521760A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
KR20110138223A (ko)	2009-03-27	2011-12-26	머크 샤프 앤드 돔 코포레이션	짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
WO2010111468A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120022142A1 (en)	2009-03-27	2012-01-26	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120022143A1 (en)	2009-03-27	2012-01-26	Merck Sharp & Dohme Corp	RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
US20100273744A1 (en)	2009-04-24	2010-10-28	Paul Martin Gore	Compounds
EP2421834A1 (de)	2009-04-24	2012-02-29	Glaxo Group Limited	Pyrazol- und triazolcarbonsäureamide als inhibitoren des crac-kanals
CN102459253B (zh)	2009-04-30	2015-03-25	葛兰素集团有限公司	作为pi3-激酶抑制剂的*唑取代的吲唑化合物
WO2011067366A1 (en)	2009-12-03	2011-06-09	Glaxo Group Limited	Indazole derivatives as pi 3 - kinase inhibitors
EP2507223A1 (de)	2009-12-03	2012-10-10	Glaxo Group Limited	Benzpyrazolderivate als p13-kinasehemmer
US20120238559A1 (en)	2009-12-03	2012-09-20	Glaxo Group Limited	Novel compounds
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
JP5965402B2 (ja)	2010-09-08	2016-08-03	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩
WO2012032065A1 (en)	2010-09-08	2012-03-15	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
EP2630127A1 (de)	2010-10-21	2013-08-28	Glaxo Group Limited	Pyrazolverbindungen, gegen allergie-, entzündungs- und immunerkrankungen
EP2630126B1 (de)	2010-10-21	2015-01-07	Glaxo Group Limited	Pyrazolverbindungen gegen allergie-, immun- und entzündungserkrankungen
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
US20140005188A1 (en)	2011-03-11	2014-01-02	Glaxo Group Limited	Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en)	2011-03-11	2011-04-27	Glaxo Group Ltd	Novel compounds
WO2015055691A1 (en)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Pi3k inhibitor for treatment of respiratory disease
EP3057587A1 (de)	2013-10-17	2016-08-24	GlaxoSmithKline Intellectual Property Development Limited	Pi3k-hemmers zur behandlung von atemwegserkrankungen
TW201625247A (zh)	2014-05-12	2016-07-16	葛蘭素史密斯克藍智慧財產權有限公司	用於治療傳染性疾病之醫藥組合物
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
JP2019524792A (ja)	2016-08-08	2019-09-05	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	化合物
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
EP4125919A1 (de)	2020-03-26	2023-02-08	GlaxoSmithKline Intellectual Property Development Limited	Cathepsinhemmer zur vorbeugung oder behandlung von virusinfektionen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1438940A (en) *	1972-07-19	1976-06-09	Glaxo Lab Ltd	17beta-haloalkoxycarbonyl-17alpha-oxysteroids
US4996335A (en) *	1980-07-10	1991-02-26	Nicholas S. Bodor	Soft steroids having anti-inflammatory activity
CA2133439C (en) *	1992-04-02	2005-07-26	Siegfried Benjamin Christensen, Iv	Compounds useful for treating allergic and inflammatory diseases
US6172054B1 (en) *	1995-06-15	2001-01-09	Alcon Laboratories, Inc.	Combination therapy for lowering and controlling intraocular pressure
US6245804B1 (en) *	1997-05-30	2001-06-12	Schering Aktiengesellschaft	Nonsteroidal gestagens
ATE237612T1 (de) *	1997-10-01	2003-05-15	Kyowa Hakko Kogyo Kk	Benzofuranderivate
US6897224B2 (en) *	2002-04-02	2005-05-24	Schering Ag	Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
GB0316290D0 (en) *	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
EP1841780B1 (de) *	2005-01-10	2011-07-27	Glaxo Group Limited	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände

2006
- 2006-01-01 US US11/813,230 patent/US20090124588A1/en not_active Abandoned
- 2006-01-09 EP EP06700486A patent/EP1836215B1/de not_active Expired - Lifetime
- 2006-01-09 ES ES06700486T patent/ES2312104T3/es not_active Expired - Lifetime
- 2006-01-09 DE DE602006002366T patent/DE602006002366D1/de not_active Expired - Lifetime
- 2006-01-09 AT AT06700486T patent/ATE405576T1/de not_active IP Right Cessation
- 2006-01-09 JP JP2007549870A patent/JP2008526807A/ja not_active Withdrawn
- 2006-01-09 WO PCT/EP2006/000150 patent/WO2006072600A1/en not_active Ceased

Also Published As

Publication number	Publication date
DE602006002366D1 (de)	2008-10-02
WO2006072600A8 (en)	2007-08-09
WO2006072600A1 (en)	2006-07-13
EP1836215A1 (de)	2007-09-26
US20090124588A1 (en)	2009-05-14
ES2312104T3 (es)	2009-02-16
EP1836215B1 (de)	2008-08-20
JP2008526807A (ja)	2008-07-24

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE405576T1 (de)	2008-09-15	Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände
GB0418045D0 (en)	2004-09-15	Compounds
ATE517908T1 (de)	2011-08-15	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
NO20063761L (no)	2006-10-23	Sulfonamidderivater for behandling av sykdommer
NO20084005L (no)	2008-09-19	Aminderivater
MY143390A (en)	2011-05-13	Sulfonamide derivatives for the treatment of diseases.
MX2009006921A (es)	2009-07-06	Derivados azaespiro.
WO2004080964A8 (en)	2005-12-01	Indole derivatives useful for the treatment of diseases
TW200505862A (en)	2005-02-16	2-amino-pyridine derivatives useful for the treatment of diseases
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
ATE538651T1 (de)	2012-01-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX2009007411A (es)	2009-07-17	Derivados de espiropiperidina-glicinamida.
ATE432278T1 (de)	2009-06-15	Verbindungen zur behandlung von krankheiten
DE602007011975D1 (de)	2011-02-24	Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
DE602006020273D1 (de)	2011-04-07	Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon
WO2008077810A3 (en)	2008-09-25	Spiro-piperidine derivatives
EA200601510A1 (ru)	2007-04-27	Производные фенилэтаноламина в качестве бета-2-агонистов
MX2009005504A (es)	2009-06-03	Derivados de espiro piperidina como antagonistas del receptor via.
ATE530552T1 (de)	2011-11-15	Pyrrolobenzimidazolone und deren verwendung als antiproliferative mittel
NO20092413L (no)	2009-07-20	Pyrazolanaloger
MX2009006920A (es)	2009-07-06	Indoles.
ATE505193T1 (de)	2011-04-15	Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
NO20064806L (no)	2006-12-21	Formamidderivater anvendelige som adenoceptor
DE602004028113D1 (de)	2010-08-26	Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung
NO20064805L (no)	2006-12-01	Sammensetninger for behandling av sykdommer